Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis

Company Overview

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$1.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: ASX:CU6
• CIK: N/A
• Web: www.claritypharmaceuticals.com
• Phone: 61 2 9209 4037
• Fax: N/A
• Employees: 41
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$42.32 million
• Net Margins: -481.09%
• Pretax Margin: N/A
• Return on Equity: -42.46%
• Return on Assets: -24.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.05
• Quick Ratio: 13.19

Sales & Book Value

• Annual Sales: A$11.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.51 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 319,670,000
• Free Float: N/A
• Market Cap: A$1.17 billion
• Optionable: Not Optionable
• Beta: 1.58